Our findings indicate the effectiveness of dinactin against lung cancer cells (Lu99 and A549) by inducing G0/G1 cell cycle arrest through the downregulation of cyclins A, B, D3, and cdk2. The gene discussed is CDK2; the disease is lung carcinoma.